Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Experimental drug Lecanemab may be a landmark breakthrough in battle against Alzheimer's
01:44pm, Wednesday, 30'th Nov 2022
Yahoo Finance's Anjalee Khemlani discusses positive news around an Alzheimer's drug, plus reports that China is considering a fourth round of COVID vaccines.
5 things to know about the new Alzheimer's drug — including why it may be risky for people who take blood thinners
11:38am, Wednesday, 30'th Nov 2022
Shares of Eisai and Biogen did not move dramatically after the drug companies reported the full results of the clinical trial for their experimental Alzheimer's disease therapy, but the findings point
Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects
10:32am, Wednesday, 30'th Nov 2022
Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adve
Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors
10:14am, Wednesday, 30'th Nov 2022
Biogen stock surged Wednesday after partner Eisai unveiled Alzheimer's treatment test results that two doctors reportedly described as "magnificent." The post Why This New Alzheimer's Update Is Likely
BIIB Stock Alert: What the Latest Alzheimer's Drug Data Means for Biogen
10:00am, Wednesday, 30'th Nov 2022
Biogen (NASDAQ: BIIB ) stock is on the move Wednesday after the company provided the latest update on its Alzheimer's drug candidate. According to a press release from the biotechnology company, lecan
Biogen Stock Is Surging Today: What's Going On? - Biogen (NASDAQ:BIIB)
09:16am, Wednesday, 30'th Nov 2022
Biogen Inc (NASDAQ: BIIB) shares are trading higher Wednesday after the company announced positive trial results for its experimental Alzheimer's
Eleven Stocks Turned $10,000 To $261,421 In 11 Months
08:00am, Wednesday, 30'th Nov 2022
Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.
Biogen stock up 3% premarket after update on Alzheimer's treatment; Stifel reiterates buy rating
06:48am, Wednesday, 30'th Nov 2022
Biogen Inc. stock BIIB, -0.17% rose 3% in premarket trade Wednesday, after a new study was unveiled late Tuesday that showed the company's experimental Alzheimer's drug being developed with Japan's Ei
Biogen and Eisai Strengthen Lead in Alzheimer's Drug Race. The Stocks Are Rising.
05:11am, Wednesday, 30'th Nov 2022
Shares in the pharmaceutical companies rose after the publication of a paper detailing the apparent benefits of lecanemab.
Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors
08:44pm, Tuesday, 29'th Nov 2022
Biogen stock was muted late Tuesday after Eisai unveiled Alzheimer's treatment results likely to spark a debate over the drug's benefits. The post Why This New Alzheimer's Update Is Likely To Spark A
New Alzheimer's drug slows decline in memory - fuelling hope doctors will one day cure dementia
08:09pm, Tuesday, 29'th Nov 2022
Doctors have hailed a "new era" of medicine after a study showed for the first time that a drug can slow the debilitating symptoms of Alzheimer's.
Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focus
07:55pm, Tuesday, 29'th Nov 2022
New data was presented on Tuesday.
Biogen (BIIB) Down on Report of Death in Alzheimer's Study
02:18pm, Tuesday, 29'th Nov 2022
Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.
Research Paper Reports Death in Biogen's Experimental Drug
09:37am, Monday, 28'th Nov 2022
Biogen Inc (NASDAQ:BIIB) is under pressure this morning, in the wake of a research paper published on Science.org this Sunday.
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success
09:07am, Monday, 28'th Nov 2022
Biogen stock toppled Monday after a report suggested its experimental Alzheimer's treatment caused a patient's fatal brain hemorrhage. The post Biogen Dives On Reports Of Alzheimer's Death While Axsom
